Nanobiotix S.A. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K is a report of a foreign private issuer filed by Nanobiotix S.A. for the month of June 2026. The filing, dated June 2, 2026, serves to incorporate by reference a press release issued on the same date (Exhibit 99.1). The registrant files annual reports under Form 20-F.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document acts as a conduit for a press release and does not contain embedded financial tables or statements.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. The specific content of the press release incorporated by reference is not included in the provided text.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. These details are contained within the attached press release (Exhibit 99.1), the text of which is not present in the input.
Key Facts for Investor Verification
- Verify the full text of the press release dated June 2, 2026, referenced as Exhibit 99.1, to understand the specific corporate event or announcement.
- Confirm the impact of the announcement on the company's clinical pipeline or financial position, as no metrics are listed in this summary filing.
- Review the signature block confirming Bart Van Rhijn, Chief Financial Officer, authorized the report on June 2, 2026.